Dr.ย Ramiย Aqeilan
PhD (Doctor of Philosophy)
Full Professor & Cancer Biology Researcher
corporate_fareHebrew University of Jerusalem, Faculty of Medicine
Rami Aqeilan
PhD (Doctor of Philosophy)
Prof. Rami I. Aqeilan is a Full Professor in the Faculty of Medicine, Department of Immunology and Cancer Research, at the Hebrew University of Jerusalem, and Head of the Institute for Medical Research Israel-Canada. He is internationally recognised for his foundational work on the WWOX tumour suppressor gene and the role of common fragile sites in cancer development.
With more than 25 years of documented cancer research activity, Prof. Aqeilan has built one of the leading laboratories in translational cancer biology. His work spans genome instability, DNA damage response, cancer metabolism, and the discovery of therapeutically relevant molecular vulnerabilities in triple-negative breast cancer, paediatric osteosarcoma, pancreatic cancer, and other malignancies. Hebrew University's research repository records 156 scholarly outputs, including 111 journal articles and 23 review articles, with a Scopus h-index of 54 and more than 14,000 citations. Since November 2023, he also serves as Scientific Director of the Cyprus Cancer Research Institute. His laboratory uses genetically engineered mouse models, patient-derived xenografts, tumour organoids, CRISPR-Cas9 screening, and human clinical samples to translate discoveries towards targeted cancer therapy concepts.
CancerFax can help patients, institutions, and research collaborators connect with Prof. Aqeilan's team at Hebrew University for academic and research-related enquiries.
Why Consider Prof. Rami I. Aqeilan?
Prof. Aqeilan is among the world's most cited researchers in tumour suppressor biology and common fragile-site cancer genetics, with a publication record that bridges molecular discovery and translational oncology.
Areas of Research Specialisation
Molecular cancer biology, tumour suppressor pathways, and precision oncology research
Prof. Aqeilan's laboratory investigates the molecular mechanisms by which genome instability and tumour suppressor gene loss drive cancer initiation and progression. His research has direct translational relevance to several cancer types with unmet clinical needs.
WWOX Tumour Suppressor Biology
Long-term characterisation of the WW domain-containing oxidoreductase gene and its roles in cancer, metabolism, and neurodevelopmental disease.
- arrow_rightRole of WWOX loss in tumour initiation and progression
- arrow_rightWWOX in triple-negative breast cancer metastasis
- arrow_rightWWOX in paediatric osteosarcoma biology
- arrow_rightWWOX and cutaneous squamous cell carcinoma suppression
- arrow_rightRegulation of glucose metabolism by WWOX
- arrow_rightMetabolic vulnerabilities in WWOX-deficient tumours
Common Fragile Sites & Genome Instability
Mapping and functional characterisation of genomic regions prone to DNA breakage under replication stress and their contribution to malignancy.
- arrow_rightGenome-wide DNA double-strand break mapping ('Breakome')
- arrow_rightOncogene-induced replication stress and fragile-site expression
- arrow_rightDNA damage response mechanisms in cancer cells
- arrow_rightBiomarker discovery for targeted therapy concepts
- arrow_rightCRISPR-Cas9 and small-molecule vulnerability screening
- arrow_rightPatient-derived xenografts and tumour organoid models
Research Methods & Scientific Approach
Laboratory and translational research platforms used by the Aqeilan Lab
Prof. Aqeilan's team employs a multi-platform experimental approach combining in vivo, in vitro, and human clinical-sample-based research to generate mechanistic insights and identify therapeutic targets.
In Vivo Cancer Models
Complex DiseaseGeneration and characterisation of genetically engineered mouse models and patient-derived xenografts to study tumour suppressor loss in vivo.
Genomics & Molecular Screening
DiagnosisGenome-wide approaches to map DNA damage, identify vulnerabilities, and characterise molecular drivers of cancer progression.
Translational Cancer Research
MultidisciplinaryTranslation of laboratory findings towards therapeutic concepts for precision oncology, with a focus on cancers with unmet clinical needs.
Research Consultation & Second Opinion (Academic)
Second OpinionAcademic research consultations and expert scientific opinions on molecular cancer biology, tumour suppressor pathways, and precision oncology concepts.
Research & Publications
Peer-reviewed contributions to cancer biology and molecular oncology
Prof. Aqeilan has published 156 scholarly works with an h-index of 54 and more than 14,000 citations. His research has appeared in leading journals including PNAS, Cancer Research, EMBO Molecular Medicine, Science Advances, and Cell Death & Disease.
A complete publication list is available via the Hebrew University CRIS profile and Google Scholar. Prof. Aqeilan's research record includes 156 outputs with over 14,000 citations and an h-index of 54.
Education & Training
Prof. Aqeilan completed his undergraduate training at the University of Jordan before pursuing doctoral studies in Cellular Biochemistry and Human Genetics at the Hebrew University-Hadassah Medical School. His postdoctoral training at Thomas Jefferson University's Kimmel Cancer Center established the foundation for his internationally recognised work on WWOX.
Clinical Experience
Prof. Aqeilan joined the Hebrew University Faculty of Medicine in 2008 and has built one of Israel's leading cancer biology laboratories. He was elected Head of the Institute for Medical Research Israel-Canada in 2020 and appointed Scientific Director of the Cyprus Cancer Research Institute in 2023.
Languages & International
Prof. Aqeilan communicates in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients seeking to engage with research teams in Israel.
CancerFax can coordinate professional medical interpreter support for international patients where required.
How CancerFax Helps You Access Dr. Rami Aqeilan
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Rami Aqeilan's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Rami Aqeilan's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Rami Aqeilan before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Rami Aqeilan's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Rami Aqeilan's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Rami Aqeilan's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Rami I. Aqeilan
Prof. Aqeilan is a PhD cancer biology researcher and Full Professor at the Hebrew University of Jerusalem. His work is in laboratory and translational research rather than direct clinical patient care. Publicly available sources do not confirm that he provides clinical oncology consultations, chemotherapy planning, or surgical procedures. CancerFax lists his profile to help patients and families understand the research behind precision oncology.
Prof. Aqeilan is internationally recognised for his foundational research on the WWOX tumour suppressor gene and its role in cancer development. His laboratory studies how loss of WWOX and related common fragile-site genes contributes to genome instability, cancer initiation, and tumour progression in breast cancer, osteosarcoma, pancreatic cancer, and other malignancies. He has more than 14,000 citations and an h-index of 54.
His research has focused on triple-negative breast cancer, paediatric osteosarcoma, pancreatic cancer, cutaneous squamous cell carcinoma, lung cancer, and broader cancer biology involving genome instability. His work on WWOX and common fragile sites is relevant to multiple cancer types where DNA damage response and tumour suppressor loss play a role.
Prof. Aqeilan is based in Jerusalem, Israel. He is a Full Professor in the Faculty of Medicine, Department of Immunology and Cancer Research, at the Hebrew University of Jerusalem, and is associated with the Lautenberg Center for Immunology and Cancer Research and the Institute for Medical Research Israel-Canada. Since November 2023, he also serves as Scientific Director of the Cyprus Cancer Research Institute.
CancerFax can facilitate research enquiries and help connect patients, caregivers, or research collaborators with Prof. Aqeilan's team at Hebrew University, subject to the institution's availability and response policy. Submit your enquiry through CancerFax and our team will direct it appropriately.
Prof. Aqeilan has received the ERC Consolidator Grant, ERC Proof of Concept Grant, the Sidney Kimmel Award for Cancer Research, the Youdim Family Prize for Excellence in Cancer Research (2017), the Ma'of Fellowship, and the Bergman Memorial Research Award. He is also an elected member of the Israel Young Academy and an active member of the American and European Associations for Cancer Research.
Connect with Rami Aqeilan Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.